Xconomy

NOVEMBER 13, 2019

Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired—but not by GSK. Debuting in COI (which stands for “community of innovation”). Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Avalon 73

Avalon San Diego Incubator Invest 73

Xconomy

SEPTEMBER 27, 2016

[ Note: The headline has been corrected to better describe the company’s type of funding. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). 9/27/16, 2:09 p.m. Bregua Corp.,

Avalon 40

Avalon Funding Startup San Diego 40

Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56

Avalon Invest Southern California Develop 56

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal. Avelas plans to use the new funding to advance development of AVB-620, the company’s lead diagnostic agent, for use in breast cancer surgeries, CEO Carmine Stengone told me yesterday.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

JULY 10, 2016

Larry’s diagnosis was cancer with a big C: “I have stage 4 pancreatic cancer and have been on chemo since June with some ups and downs,” he wrote in mid-March. He found he didn’t enjoy being a traditional VC gatekeeper who said “yes” or “no” to startup pitches, according to his wife, Diane. “He He had great fun doing his companies.

San Diego 40

San Diego Startup Avalon Venture Capital 40

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. But so far, the company has actually drawn only $3 million last year and $4 million earlier this year.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

Xconomy

SEPTEMBER 30, 2016

Who will break free of the pack of companies developing drugs meant to prevent migraines? —Shares of New York-based Intra-Cellular Therapies (NASDAQ: ITCI ) plummeted almost 70 percent after its experimental schizophrenia drug came up short in the second of two Phase 3 trials. Phase 3 trials should start next year.

Avalon 40

Avalon Thousand Oaks Study Startup 40